Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?

Tocilizumab is widely being used to treat COVID-19. Although reducing systemic inflammation, it also increases the risk for secondary infections as a result of the immunosuppression produced. We report the case of a 69-year-old patient admitted to the ICU with severe respiratory distress caused by C...

Descripción completa

Detalles Bibliográficos
Autores principales: Deana, Cristian, Vetrugno, Luigi, Bassi, Flavio, De Monte, Amato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
CAPA Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826035/
https://www.ncbi.nlm.nih.gov/pubmed/33520634
http://dx.doi.org/10.1016/j.mmcr.2021.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826035/
https://www.ncbi.nlm.nih.gov/pubmed/33520634
http://dx.doi.org/10.1016/j.mmcr.2021.01.002

Ejemplares similares